
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Alzheimer's disease symptoms are managed with galantamine (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities).
galantamine belongs to the group of drugs known as acetylcholinesterase inhibitors. It functions by enhancing the brain's supply of a particular naturally occurring compound required for memory and cognition.
galantamine may help AD patients think and remember more clearly or slow the loss of these skills. galantamine will not, however, reverse AD or stop the eventual loss of mental capacity.
The three oral dosage forms of galantamine include tablets, extended-release (long-acting) capsules, and solutions (liquids). The drink and tablets are typically taken twice daily, ideally with breakfast and dinner.
Typically, one extended-release capsule is taken in the morning. Take galantamine every day at around the same time(s). Ask your doctor or pharmacist to explain any instructions on your prescription label that you are unsure about following.
Follow the galantamine directions exactly. Never take it in larger or less amounts or more frequently than directed by your doctor. If you adhere to your doctor's specific dosing regimen, you will experience galantamine side effects less frequently.
Galantamine is used to treat mild to severe Alzheimer's disease-related cognitive loss as well as a variety of other memory problems.
The Global galantamine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Galantamine, an oral acetylcholinesterase inhibitor used to treat Alzheimer's disease, is offered by pubchem. galantamine has not been linked to any clinically obvious liver damage and is related with a low risk of blood enzyme increases while receiving treatment.
Acetylcholine neurotransmission is boosted by galantamine because it prevents acetylcholine in the synaptic cleft from being broken down.
It also affects the nicotinic receptor allosterically, which gives its dual method of action therapeutic importance. In 2001, the FDA gave the medication approval for the management of mild to moderate Alzheimer's disease.
galantamine is not known to change the course of the underlying dementing process in Alzheimer's disease because it is a neurodegenerative disorder that progresses over time.
galantamine improves cholinergic neuron activity and signalling by inhibiting the enzyme that breaks down acetylcholine in the synaptic cleft.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |